What are the results of Structure Therapeutics' aleniglipron trial?

Structure Therapeutics reported positive topline results, showing significant weight loss in participants with obesity taking aleniglipron.

How effective is aleniglipron for weight loss?

In a Phase IIb study, aleniglipron achieved up to 11.3% mean weight loss at 36 weeks, with higher doses showing even greater efficacy.

When will Structure Therapeutics meet with the FDA about aleniglipron?

Structure Therapeutics plans to seek an End-of-Phase II meeting with the FDA in the first half of next year to finalize Phase III design.

Home / Health / New Obesity Drug Aleniglipron Shows Promising Weight Loss

New Obesity Drug Aleniglipron Shows Promising Weight Loss

9 Dec

•

Summary

Aleniglipron demonstrated 11.3% mean weight loss in Phase IIb study.
Up to 15.3% weight loss observed with higher doses in exploratory trial.
Structure Therapeutics plans Phase III meeting with FDA soon.

New Obesity Drug Aleniglipron Shows Promising Weight Loss

Structure Therapeutics has reported significant positive outcomes from its ACCESS clinical programme, evaluating the investigational oral GLP-1 receptor agonist, aleniglipron.

The core Phase IIb study revealed that participants receiving aleniglipron at a 120mg dose achieved an 11.3% placebo-adjusted mean weight loss after 36 weeks. Exploratory trials indicated even greater weight loss, up to 15.3% with a 240mg dose, while maintaining a tolerability profile consistent with the GLP-1 receptor agonist class.

Further analysis from extension studies showed persistent weight loss and enhanced tolerability when treatment initiated at a lower 2.5mg dose. No drug-induced liver injury or liver enzyme increases were reported across all studies. The company is preparing for a pivotal Phase III design meeting with the US FDA.